Discovering TEX19: A Promising Drug Target and Biomarker (G400629)
Discovering TEX19: A Promising Drug Target and Biomarker
TEX19 (TEX19-HUMAN), a synthetic peptide derived from the human T-cell antigen TEX19, has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Its unique structure, derived from a single amino acid residue, makes it a stable and soluble protein that can be easily administered to humans.
The identification of TEX19 as a potential drug target comes from its ability to interact with various proteins, including the protein PD-L1. PD-L1 is a key driver of immune evasion by cancer cells, and its overexpression has been implicated in the development and progression of many diseases, including cancer. TEX19 has been shown to reduce the expression of PD-L1 in various cell types, including cancer cells, and to stimulate the production of T-cells, which are known to play a critical role in immune surveillance.
Furthermore, TEX19 has been shown to interact with the protein FASN, which is involved in the development and progression of neurodegenerative diseases. The deletion of the FASN gene has been linked to the development of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. TEX19 has been shown to increase the expression of FASN, which may have neuroprotective effects against neurodegenerative diseases.
In addition to its potential drug target properties, TEX19 also has potential as a biomarker. Its unique structure and stability make it a stable protein that can be easily measured and detected in various cell types, including cancer cells, immune cells, and neurodegenerative cells. This makes it an attractive candidate for use as a biomarker for disease diagnosis and monitoring.
The ability of TEX19 to interact with various proteins also makes it a potential target for small molecule inhibitors. By modulating the expression and activity of these proteins, TEX19 can be effectively inhibited, which may have therapeutic benefits for various diseases.
In conclusion, TEX19 is a promising drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Its unique structure and stability make it an attractive candidate for use as a therapeutic agent, while its ability to interact with various proteins also makes it a potential biomarker for disease diagnosis and monitoring. Further research is needed to fully understand the therapeutic potential of TEX19 and its potential as a drug and biomarker.
Protein Name: Testis Expressed 19
Functions: Required during spermatogenesis and placenta development, participating in the repression of retrotransposable elements and prevent their mobilization. Collaborates with the Piwi-interacting RNA (piRNA) pathway, which mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins. Interacts with Piwi proteins and directly binds piRNAs, a class of 24 to 30 nucleotide RNAs that are generated by a Dicer-independent mechanism and are primarily derived from transposons and other repeated sequence elements. Also during spermatogenesis, promotes, with UBR2, SPO11-dependent recombination foci to accumulate and drive robust homologous chromosome synapsis (By similarity). Interacts with LINE-1 retrotransposon encoded LIRE1, stimulates LIRE1 polyubiquitination, mediated by UBR2, and degradation, inhibiting LINE-1 retrotransposon mobilization (PubMed:28806172)
The "TEX19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TEX19 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C | TFAP2D | TFAP2E | TFAP4 | TFB1M | TFB2M | TFCP2 | TFCP2L1 | TFDP1 | TFDP1P2 | TFDP2 | TFDP3 | TFE3 | TFEB | TFEC | TFF1 | TFF2 | TFF3 | TFG | TFIID Basal Transcription Factor Complex | TFIIIC2 complex | TFIP11 | TFIP11-DT | TFPI | TFPI2 | TFPT | TFR2 | TFRC | TG | TGDS | TGFA | TGFA-IT1 | TGFB1 | TGFB1I1 | TGFB2 | TGFB2-AS1 | TGFB3 | TGFBI | TGFBR1 | TGFBR2 | TGFBR3 | TGFBR3L | TGFBRAP1 | TGIF1 | TGIF2 | TGIF2-RAB5IF | TGIF2LX | TGIF2LY | TGM1 | TGM2 | TGM3 | TGM4 | TGM5 | TGM6 | TGM7 | TGOLN2 | TGS1 | TH | TH2LCRR | THADA | THAP1 | THAP10 | THAP11 | THAP12
